Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$5.49Last Year’s EPS
$2.49Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -16.02%
|Next Earnings Date:Jan 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and product performance, driven by new product launches and pipeline advancements. However, there were some challenges such as the decline in Trulicity revenue and inventory management issues impacting sales. Despite these, the company's financial health and future prospects remain robust.Company Guidance
During the Q3 2024 earnings call, Eli Lilly provided robust financial guidance, detailing a 42% revenue growth, excluding the olanzapine portfolio impact, and emphasizing a new product revenue increase of over $3 billion driven by Mounjaro and Zepbound. The company projected full-year revenue between $45.4 billion and $46 billion, representing approximately 50% growth in Q4 compared to the previous year. With a gross margin up to 82.2%, despite higher R&D and marketing expenses, Lilly also noted a 17% increase in non-incretin portfolio revenue. The effective tax rate was 37.6% due to nondeductible charges, while EPS reached $1.19, including a $3.08 impact from acquired IPR&D charges. The company is optimistic about exceeding production targets for incretin medicines and anticipates continued growth fueled by new market launches and demand generation activities.Significant Revenue Growth
Revenue grew 42% after excluding the impact of the olanzapine portfolio, with new product revenue increasing by over $3 billion, led by Mounjaro and Zepbound.
Strong Product Performance
U.S. demand for Mounjaro and Zepbound showed continued growth with a 25% quarter-over-quarter prescription volume increase in Q3.
Pipeline Advancements
Approval of Eliquis for atopic dermatitis, approval in Japan and Great Britain for Alzheimer's disease treatments, and positive Phase III data for tirzepatide and donanemab.
Manufacturing Expansion
Invested nearly $2 billion in manufacturing expansion in Ireland, with total commitments exceeding $20 billion since 2020.
Positive Financial Metrics
Gross margin increased to 82.2%, and earnings per share rose to $1.19 from $0.10 in Q3 2023.
---
LLY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LLY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $902.09 | $845.43 | -6.28% |
| Aug 08, 2024 | $769.79 | $842.73 | +9.48% |
| Apr 30, 2024 | $733.70 | $777.40 | +5.96% |
| Feb 06, 2024 | $701.62 | $700.46 | -0.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Eli Lilly & Co (LLY) report earnings?
Eli Lilly & Co (LLY) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Eli Lilly & Co (LLY) earnings time?
Eli Lilly & Co (LLY) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LLY EPS forecast?
LLY EPS forecast for the fiscal quarter 2024 (Q4) is $5.49.
---
